News & Events

Press releases

Pneumagen Ltd Announces Positive Anti–Viral Activity for Novel Glycan Approach in Preventing COVID–19 Infections

READ MORE...

Pneumagen Ltd Leverages its Novel Glycan Approach to Target Coronavirus (COVID-19) Infections

READ MORE...

Pneumagen Presents Poster on Multivalent Sialic Acid-binding Proteins as a Novel Preventative and Treatment of RSV at RSVVW 2019

READ MORE...

Pneumagen Demonstrates Preclinical Proof-of-Concept in Oncology for Neumonco, a Novel Carbohydrate Binding Module

READ MORE...

Pneumagen Demonstrates Preclinical Proof-of-Concept for Neumifil™ in Respiratory Syncytial Virus Infections

READ MORE...

Pneumagen Appoints Scientific Advisory Board

READ MORE...

Publication – Sialic Acid-Binding Protein Sp2CBMTD Protects Mice against Lethal Challenge with Emerging Influenza A (H7N9) Virus

READ MORE...

PUBLICATION – Prevention of influenza by targeting host receptors using engineered proteins

READ MORE...

Event information

Jefferies London Healthcare Conference | November 15th – 17th 2022

READ MORE...

BIO-Europe in Leipzig | October 24th – 26th 2022

READ MORE...

BIO International Convention in San Diego | June 13th – 16th 2022

READ MORE...

Bio€quity Europe in Milan | May 16th – 18th 2022

READ MORE...

BioTrinity 2022 in London | April 26th – 27th 2022

READ MORE...

BIO-Europe Spring Digital | March 28th – 30th 2022

READ MORE...